Found 489 with Last Name = 'cui' and Initial = 'w' 
Affinity DataKi: 1.40nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 3nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 5.90nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 6.90nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 7.60nMAssay Description:Displacement of [3H]Nisoxetine from human NET expressed in HEK293E cells after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 14nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 15nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 16nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 18nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 21nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 25nMAssay Description:Inhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 28nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 31nMAssay Description:Inhibitory constant against human Alpha-2A adrenergic receptor expressed in LM(tk-) cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 32nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 32nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 34nMAssay Description:Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 36nMAssay Description:Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 41nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 41nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 52nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 66nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 79nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 85nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 91nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 102nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 123nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 123nMAssay Description:Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorMore data for this Ligand-Target Pair
Affinity DataKi: 141nMAssay Description:Inhibitory constant against human Alpha-2B adrenergic receptor expressed in Y-1 cells using [3H]rauwolscineMore data for this Ligand-Target Pair
Affinity DataKi: 230nMAssay Description:Displacement of [3H]Citolapram from human SERT expressed in HEK293E cells after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 340nMAssay Description:Displacement of [3H]Nisoxetine from human NET expressed in HEK293E cells after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Displacement of [3H]Citolapram from human SERT expressed in HEK293E cells after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.380nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.430nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.540nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.570nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Sun Yat-Sen University
Curated by ChEMBL
Sun Yat-Sen University
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of PDE9A2 catalytic domain (unknown origin) using [3H]-cGMP/[3H]-cAMP as substrate after 15 mins by liquid scintillation counting analysisMore data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.630nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.640nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.670nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.730nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.740nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.740nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.780nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.780nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.810nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.820nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.880nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
